268 related articles for article (PubMed ID: 26453583)
81. Double negative (DN) αβ T cells: misperception and overdue recognition.
Martina MN; Noel S; Saxena A; Rabb H; Hamad AR
Immunol Cell Biol; 2015 Mar; 93(3):305-10. PubMed ID: 25420721
[TBL] [Abstract][Full Text] [Related]
82. Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy.
Brunet-Possenti F; Charpentier C; Bouhnik Y; Deschamps L; Descamps D; Moins-Teisserenc H; Descamps V
JAMA Dermatol; 2019 May; 155(5):629-631. PubMed ID: 30865238
[No Abstract] [Full Text] [Related]
83. Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome.
Cerutti E; Campagnoli MF; Ferretti M; Garelli E; Crescenzio N; Rosolen A; Chiocchetti A; Lenardo MJ; Ramenghi U; Dianzani U
BMC Immunol; 2007 Nov; 8():28. PubMed ID: 17999750
[TBL] [Abstract][Full Text] [Related]
84. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.
Bannwarth B; Kostine M; Poursac N
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):753-61. PubMed ID: 23570265
[TBL] [Abstract][Full Text] [Related]
85. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
Cohen SB; Koenig A; Wang L; Kwok K; Mebus CA; Riese R; Fleischmann R
Clin Exp Rheumatol; 2016; 34(1):32-6. PubMed ID: 26575982
[TBL] [Abstract][Full Text] [Related]
86. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
Strober BE; Gottlieb AB; van de Kerkhof PCM; Puig L; Bachelez H; Chouela E; Imafuku S; Thaçi D; Tan H; Valdez H; Gupta P; Kaur M; Frajzyngier V; Wolk R
Br J Dermatol; 2019 Jan; 180(1):67-75. PubMed ID: 30188571
[TBL] [Abstract][Full Text] [Related]
87. Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
van Vollenhoven R; Lee EB; Strengholt S; Mojcik C; Valdez H; Krishnaswami S; Biswas P; Lazariciu I; Hazra A; Clark JD; Hodge J; Wang L; Choy E
Arthritis Rheumatol; 2019 May; 71(5):685-695. PubMed ID: 30427585
[TBL] [Abstract][Full Text] [Related]
88. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
[TBL] [Abstract][Full Text] [Related]
89. An urticarial drug eruption caused by tofacitinib for alopecia universalis.
Doolan BJ; Cranwell WC; Varigos GA; De Cruz R
Dermatol Ther; 2019 Jul; 32(4):e12933. PubMed ID: 30977965
[No Abstract] [Full Text] [Related]
90. Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo
Raychaudhuri S; Abria C; Harmany ZT; Smith CM; Kundu-Raychaudhuri S; Raychaudhuri SP; Chaudhari AJ
Int J Rheum Dis; 2019 Dec; 22(12):2165-2169. PubMed ID: 31659868
[TBL] [Abstract][Full Text] [Related]
91. Intestinal intraepithelial lymphocyte T cells are resistant to lpr gene-induced T cell abnormalities.
Aicher WK; Fujihashi K; Taguchi T; McGhee JR; Yamamoto M; Eldridge JH; Gay S; Kiyono H
Eur J Immunol; 1992 Jan; 22(1):137-45. PubMed ID: 1346108
[TBL] [Abstract][Full Text] [Related]
92. Tofacitinib Ameliorates Lupus Through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor.
Yan Q; Chen W; Song H; Long X; Zhang Z; Tang X; Chen H; Lin H; Sun L
Front Immunol; 2021; 12():675542. PubMed ID: 34394075
[TBL] [Abstract][Full Text] [Related]
93. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
Ibrahim SSA; Salama MA; Selima E; Shehata RR
Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
[TBL] [Abstract][Full Text] [Related]
94. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
95. Recovery of nail dystrophy potential new therapeutic indication of tofacitinib.
Jaller JA; Jaller JJ; Jaller AM; Jaller-Char JJ; Ferreira SB; Ferreira R; Scheinberg M
Clin Rheumatol; 2017 Apr; 36(4):971-973. PubMed ID: 28210825
[TBL] [Abstract][Full Text] [Related]
96. Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice.
Chesnutt MS; Finck BK; Killeen N; Connolly MK; Goodman H; Wofsy D
Clin Immunol Immunopathol; 1998 Apr; 87(1):23-32. PubMed ID: 9576007
[TBL] [Abstract][Full Text] [Related]
97. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Liu LY; Strassner JP; Refat MA; Harris JE; King BA
J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
[TBL] [Abstract][Full Text] [Related]
98. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.
Yoshida H; Kimura A; Fukaya T; Sekiya T; Morita R; Shichita T; Inoue H; Yoshimura A
Biochem Biophys Res Commun; 2012 Feb; 418(2):234-40. PubMed ID: 22252297
[TBL] [Abstract][Full Text] [Related]
99. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
Bissonnette R; Iversen L; Sofen H; Griffiths CE; Foley P; Romiti R; Bachinsky M; Rottinghaus ST; Tan H; Proulx J; Valdez H; Gupta P; Mallbris L; Wolk R
Br J Dermatol; 2015; 172(5):1395-406. PubMed ID: 25418186
[TBL] [Abstract][Full Text] [Related]
100. Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation.
Paskiewicz A; Niu J; Chang C
Autoimmun Rev; 2023 Nov; 22(11):103442. PubMed ID: 37683818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
